table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID 19 outpatients
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 1 CT-P59 3.2 part 2

1 studies excluded by filtering options 2

5570 CT-P59 1.2, 2020 210excludedrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons